Trial Profile
Efficacy of Erlotinib and Gefitinib in Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer patients with CNS Metastases.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2017
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Gefitinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Nov 2017 New trial record
- 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer.